MétaCan
Menu
Back to cohort
Record W4327934571 · doi:10.1055/s-0043-1761000

Acute Exacerbations in Patients with Progressive Fibrosing Interstitial Lung Diseases: Data from the INBUILD Trial*

2023· article· en· W4327934571 on OpenAlexaff
Michael Kreuter, Elisabeth Bendstrup, Stefania Cerri, K Flaherty, Shane Shapera, Jeongah Song, Heiko Mueller, K B Rohr, Y Kondoh

Bibliographic record

VenuePneumologie · 2023
Typearticle
Languageen
FieldMedicine
TopicInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Canadian institutionsUniversity of TorontoUniversity Health Network
Fundersnot available
KeywordsMedicineIdiopathic pulmonary fibrosisPulmonary fibrosisLungInterstitial lung diseasePopulationPathologyFibrosisInternal medicine

Abstract

fetched live from OpenAlex

Rationale Few data are available on acute exacerbations (A-EX) in patients with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis (IPF). Data from the INBUILD trial characterize A-EX in this population. Methods Patients had diffuse fibrosing ILD (other than IPF) of>10% on HRCT, FVC≥45%, and DLco≥30%–<80% predicted, and criteria for progression of ILD within the prior 24 months, despite appropriate management in clinical practice. Patients were randomized to nintedanib or placebo. An A-EX of ILD was defined in the protocol as a clinically significant respiratory deterioration characterized by new, widespread alveolar abnormality meeting all these criteria: i) acute worsening or development of dyspnea (typically of<1 month duration); ii) CT with new bilateral ground-glass opacity or consolidation superimposed on a background pattern consistent with fibrosing ILD, iii) not fully explained by cardiac failure or fluid overload. Infection was not an exclusion criterion. A-EX were reported by investigators as part of the pre-specified reporting of adverse events and were not adjudicated. We compared the baseline characteristics of patients who did versus did not have an A-EX during the trial (both groups pooled) and analyzed the times from A-EX to hospitalization and death ([ Abb. 1 ]). Abb. 1 Time from first acute exacerbation of ILD to i) hospitalization and ii)deaht in patents with progressive fibrosing ILDS in the INBUILD trial. Results A-EX were reported in 58 of 663 (8.7%) patients during the follow-up (median: approximately 19 months). Of these, 18 (31.0%) had hypersensitivity pneumonitis, 15 (25.9%) unclassifiable idiopathic interstitial pneumonia, 12 (20.7%) an autoimmune disease-related ILD, 6 (10.3%) idiopathic non-specific interstitial pneumonia, and 7 (12.1%) other ILDs. Compared with the patients who did not have anA-EX, the patients who had an A-EX included a greater proportion of males (65.5% vs 52.6%), current or former smokers (53.4% vs 50.7%), and patients with a usual interstitial pneumonia (UIP)-like fibrotic pattern on HRCT (65.5% vs 61.8%) and had a lower FVC (65.7% vs 69.3% predicted) and lower DLco (40.7% vs 46.6% predicted) at baseline. Kaplan-Meier estimates of rates of hospitalization and death within 180 days of an A-EX were 90.6% and 37.0%, respectively (Figure). Conclusions The INBUILD trial suggest that in patients with PF-ILDs other than IPF, A-EX are associated with a high risk of hospitalization and death. Publication History Article published online: 09 March 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.014

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.005
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.032
GPT teacher head0.313
Teacher spread0.282 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venuePneumologieSame topicInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisFrench-language works237,207